Amgen Inc (AMGN) 169.24 $AMGN
Amgen Announces New Data From Phase 2 BLINCYTO(TM) (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease
PR Newswire - Sat Dec 06, 12:00PM CST
Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE®) immunotherapy BLINCYTO(TM) (blinatumomab) in patients with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). In the study, 78 percent of patients who received BLINCYTO experienced a complete MRD response (95 percent CI: 69-85 percent), a measure of eradication of residual disease at the molecular level, after one treatment cycle. Nearly all complete responses (98 percent) occurred within the first treatment cycle.
AMGN: 169.24 (+2.69)
3 Top Large-Cap Biotech Stocks for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 06, 10:25AM CST
Biotechnology stocks have been among the market's top performers this year, with the iShares Nasdaq Biotechnology ETF's 36% gain handily outpacing the S&P 500 's 14% return. That heady return, however, comes with one potential drawback: It might...
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97), CELG: 114.13 (+0.50)
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
PR Newswire - Sat Dec 06, 10:00AM CST
Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial, which evaluated Kyprolis® (carfilzomib) for Injection plus Revlimid® (lenalidomide) and dexamethasone (KRd) compared with Revlimid and dexamethasone (Rd) in patients with relapsed multiple myeloma. As previously reported, the ASPIRE study met its primary endpoint by demonstrating that KRd significantly extended the time patients lived without their disease worsening, or progression-free survival (PFS), by 26.3 months compared to 17.6 months with Rd (HR=0.69; 95 percent CI: 0.57-0.83; p<0.0001), an 8.7 month improvement in PFS.
AMGN: 169.24 (+2.69)
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting
at The Street - Sat Dec 06, 10:00AM CST
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
AMGN: 169.24 (+2.69), SNY: 46.75 (unch), CELG: 114.13 (+0.50)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 05, 7:22PM CST
Cramer will be watching for news from Agios Pharmaceuticals and Amgen and awaiting an explanation from United Technologies about its former CEO.
KMI: 41.12 (-0.34), RH: 85.18 (+2.20), UTX: 111.29 (+0.08), CAH: 82.23 (unch), HAL: 40.37 (-0.37), AMGN: 169.24 (+2.69), PAA: 50.42 (-0.72), SLB: 87.16 (-0.27), RFMD: 15.62 (+0.09), AZO: 587.95 (-0.12), GILD: 104.59 (+2.77), S: 4.85 (-0.01), SHPG: 215.07 (-0.94), COST: 143.25 (+0.23), ABBV: 69.71 (+0.14), AGIO: 106.02 (+1.97), DOV: 75.71 (-0.23), ULTA: 129.75 (+4.01), IDXX: 148.62 (-0.09), LE: 49.45 (+0.07), CRM: 58.85 (-0.10)
Final Glance: Biotechnology companies
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), CELG: 114.13 (+0.50)
Midday Glance: Biotechnology companies
AP - Fri Dec 05, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), CELG: 114.13 (+0.50)
Early Glance: Biotechnology companies
AP - Fri Dec 05, 9:27AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), CELG: 114.13 (+0.50)
Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 9:20AM CST
The HealthCare segment at Bayer (BAYRY) announced that the company has submitted Marketing Authorization Application in Europe for BAY 81-8973.
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), AMAG: 41.18 (+0.59)
Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:45PM CST
Amgen's (AMGN) Blincyto gained FDA approval for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), ILMN: 189.90 (-0.93), AMGN: 169.24 (+2.69)
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 340.87 (-0.31), ADMA: 10.40 (-0.40), ANIP: 53.29 (-0.16), AMGN: 169.24 (+2.69)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - Thu Dec 04, 3:47PM CST
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 340.87 (-0.31), ARE: 88.13 (+0.01), GILD: 104.59 (+2.77), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - Thu Dec 04, 2:14PM CST
AGN: 213.35 (-0.36), BIIB: 340.87 (-0.31), GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), NVS: 95.83 (+0.06)
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:10PM CST
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 4.66 (+0.10), BIIB: 340.87 (-0.31), GEVA: 84.78 (+3.01), AMGN: 169.24 (+2.69)
Insider Trading Alert - CVT, ARAY And AMGN Traded By Insiders
at The Street - Thu Dec 04, 9:15AM CST
Stocks with insider trader activity include CVT, ARAY and AMGN
CVT: 27.97 (+0.84), AMGN: 169.24 (+2.69), ARAY: 6.77 (-0.13)
The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
PR Newswire - Thu Dec 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), LLY: 71.85 (-0.53)
Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:15AM CST
Shares of Regeneron have been riding high after the company announced that its supplemental biologics license application for Eylea will be reviewed by the FDA on a priority basis.
AMGN: 169.24 (+2.69), AMAG: 41.18 (+0.59), REGN: 423.23 (+0.02)
Why Biotech Stocks Don't Pay Dividends
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 04, 8:13AM CST
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don't have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made...
JNJ: 108.51 (+0.95), GILD: 104.59 (+2.77), AZN: 73.72 (-0.22), AMGN: 169.24 (+2.69)
Amgen Announces New Data From Phase 2 BLINCYTO(TM) (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease
PR Newswire - Sat Dec 06, 12:00PM CST
Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE®) immunotherapy BLINCYTO(TM) (blinatumomab) in patients with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). In the study, 78 percent of patients who received BLINCYTO experienced a complete MRD response (95 percent CI: 69-85 percent), a measure of eradication of residual disease at the molecular level, after one treatment cycle. Nearly all complete responses (98 percent) occurred within the first treatment cycle.
AMGN: 169.24 (+2.69)
3 Top Large-Cap Biotech Stocks for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 06, 10:25AM CST
Biotechnology stocks have been among the market's top performers this year, with the iShares Nasdaq Biotechnology ETF's 36% gain handily outpacing the S&P 500 's 14% return. That heady return, however, comes with one potential drawback: It might...
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97), CELG: 114.13 (+0.50)
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
PR Newswire - Sat Dec 06, 10:00AM CST
Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial, which evaluated Kyprolis® (carfilzomib) for Injection plus Revlimid® (lenalidomide) and dexamethasone (KRd) compared with Revlimid and dexamethasone (Rd) in patients with relapsed multiple myeloma. As previously reported, the ASPIRE study met its primary endpoint by demonstrating that KRd significantly extended the time patients lived without their disease worsening, or progression-free survival (PFS), by 26.3 months compared to 17.6 months with Rd (HR=0.69; 95 percent CI: 0.57-0.83; p<0.0001), an 8.7 month improvement in PFS.
AMGN: 169.24 (+2.69)
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting
at The Street - Sat Dec 06, 10:00AM CST
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
AMGN: 169.24 (+2.69), SNY: 46.75 (unch), CELG: 114.13 (+0.50)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 05, 7:22PM CST
Cramer will be watching for news from Agios Pharmaceuticals and Amgen and awaiting an explanation from United Technologies about its former CEO.
KMI: 41.12 (-0.34), RH: 85.18 (+2.20), UTX: 111.29 (+0.08), CAH: 82.23 (unch), HAL: 40.37 (-0.37), AMGN: 169.24 (+2.69), PAA: 50.42 (-0.72), SLB: 87.16 (-0.27), RFMD: 15.62 (+0.09), AZO: 587.95 (-0.12), GILD: 104.59 (+2.77), S: 4.85 (-0.01), SHPG: 215.07 (-0.94), COST: 143.25 (+0.23), ABBV: 69.71 (+0.14), AGIO: 106.02 (+1.97), DOV: 75.71 (-0.23), ULTA: 129.75 (+4.01), IDXX: 148.62 (-0.09), LE: 49.45 (+0.07), CRM: 58.85 (-0.10)
Final Glance: Biotechnology companies
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), CELG: 114.13 (+0.50)
Midday Glance: Biotechnology companies
AP - Fri Dec 05, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), CELG: 114.13 (+0.50)
Early Glance: Biotechnology companies
AP - Fri Dec 05, 9:27AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), CELG: 114.13 (+0.50)
Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 9:20AM CST
The HealthCare segment at Bayer (BAYRY) announced that the company has submitted Marketing Authorization Application in Europe for BAY 81-8973.
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), AMAG: 41.18 (+0.59)
Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:45PM CST
Amgen's (AMGN) Blincyto gained FDA approval for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), ILMN: 189.90 (-0.93), AMGN: 169.24 (+2.69)
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 340.87 (-0.31), ADMA: 10.40 (-0.40), ANIP: 53.29 (-0.16), AMGN: 169.24 (+2.69)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - Thu Dec 04, 3:47PM CST
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 340.87 (-0.31), ARE: 88.13 (+0.01), GILD: 104.59 (+2.77), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - Thu Dec 04, 2:14PM CST
AGN: 213.35 (-0.36), BIIB: 340.87 (-0.31), GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), NVS: 95.83 (+0.06)
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:10PM CST
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 4.66 (+0.10), BIIB: 340.87 (-0.31), GEVA: 84.78 (+3.01), AMGN: 169.24 (+2.69)
Insider Trading Alert - CVT, ARAY And AMGN Traded By Insiders
at The Street - Thu Dec 04, 9:15AM CST
Stocks with insider trader activity include CVT, ARAY and AMGN
CVT: 27.97 (+0.84), AMGN: 169.24 (+2.69), ARAY: 6.77 (-0.13)
The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
PR Newswire - Thu Dec 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), LLY: 71.85 (-0.53)
Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:15AM CST
Shares of Regeneron have been riding high after the company announced that its supplemental biologics license application for Eylea will be reviewed by the FDA on a priority basis.
AMGN: 169.24 (+2.69), AMAG: 41.18 (+0.59), REGN: 423.23 (+0.02)
Why Biotech Stocks Don't Pay Dividends
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 04, 8:13AM CST
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don't have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made...
JNJ: 108.51 (+0.95), GILD: 104.59 (+2.77), AZN: 73.72 (-0.22), AMGN: 169.24 (+2.69)
